Resistant hypertension optimal treatment trial: a randomized controlled trial

Clinical Cardiology
Eduardo M KriegerJosé Geraldo Mill

Abstract

The prevalence of resistant hypertension (ReHy) is not well established. Furthermore, diuretics, angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers, and calcium channel blockers are largely used as the first 3-drug combinations for treating ReHy. However, the fourth drug to be added to the triple regimen is still controversial and guided by empirical choices. We sought (1) to determine the prevalence of ReHy in patients with stage II hypertension; (2) to compare the effects of spironolactone vs clonidine, when added to the triple regimen; and (3) to evaluate the role of measuring sympathetic and renin-angiotensin-aldosterone activities in predicting blood pressure response to spironolactone or clonidine. The Resistant Hypertension Optimal Treatment (ReHOT) study (ClinicalTrials.gov NCT01643434) is a prospective, multicenter, randomized trial comprising 26 sites in Brazil. In step 1, 2000 patients will be treated according to hypertension guidelines for 12 weeks, to detect the prevalence of ReHy. Medical therapy adherence will be checked by pill count monitoring. In step 2, patients with confirmed ReHy will be randomized to an open label 3-month treatment with spironolactone (titrating dose, 12.5-50 mg onc...Continue Reading

Associated Clinical Trials

Jul 18, 2012·Eduardo Moacyr Krieger

References

Jan 12, 1979·JAMA : the Journal of the American Medical Association·J H LaraghT G Pickering
Jul 1, 1977·The American Journal of Cardiology·A Zweifler, M Esler
Oct 29, 1997·JAMA : the Journal of the American Medical Association·R N Butler
Oct 3, 1999·Annals of Internal Medicine·N C NetzerK P Strohl
May 23, 2002·Hypertension·Sandra J TalerJo Ellen Augustine
Sep 3, 2002·Journal of the American College of Cardiology·Harlan M KrumholzA David Paltiel
Dec 20, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatm
Feb 21, 2007·Hypertension·Neil ChapmanUNKNOWN Anglo-Scandinavian Cardiac Outcomes Trial Investigators
Aug 10, 2007·Current Hypertension Reports·Dan Carl, Domenic A Sica
Jul 16, 2008·Circulation·Lawrence J Appel
Sep 4, 2009·Cleveland Clinic Journal of Medicine·Qi CheMohammed A Rafey
Apr 13, 2010·The American Journal of Cardiology·Luciano F DragerGeraldo Lorenzi-Filho
Mar 2, 2012·Circulation·Stacie L DaughertyP Michael Ho
Mar 2, 2012·Circulation·Eduardo Pimenta, David A Calhoun
Jul 13, 2012·Journal of Hypertension·Giuseppe Mancia

❮ Previous
Next ❯

Citations

Feb 9, 2017·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·E M RegoP L da Luz
Mar 30, 2017·Current Hypertension Reports·Hamish Cg ProsserMarkus P Schlaich
Nov 23, 2017·Clinical and Experimental Pharmacology & Physiology·José Luiz de Brito Alves, João Henrique Costa-Silva
May 18, 2018·Current Medical Research and Opinion·Carol A ForbesEmil Hagström
Jun 18, 2018·Current Hypertension Reports·Andrea Pio-Abreu, Luciano F Drager
Jul 23, 2015·Current Hypertension Reports·Nihal El Rouby, Rhonda M Cooper-DeHoff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.